RT Book, Section
A1 Adams, Val R.
A1 Hecht, Keith A.
A2 DiPiro, Joseph T.
A2 Yee, Gary C.
A2 Posey, L. Michael
A2 Haines, Stuart T.
A2 Nolin, Thomas D.
A2 Ellingrod, Vicki
SR Print(0)
ID 1191341721
T1 Lung Cancer
T2 Pharmacotherapy: A Pathophysiologic Approach, 11e
YR 2020
FD 2020
PB McGraw-Hill Education
PP New York, NY
SN 9781260116816
LK accesspharmacy.mhmedical.com/content.aspx?aid=1191341721
RD 2024/04/24
AB Update  SummaryThe  following  updates  were  made  on  February  4,  2021:Nonsmall  Cell  Lung  Cancer,  Local  Disease  (Stages  I-II):  revised  chemotherapy  options  and  added  osimertinib  for  EGFR+  diseaseNonsmall  Cell  Lung  Cancer,  Advanced  (Stage  IV)  Disease  and  Relapsed  Disease:  added  atezolizumab  as  option  to  PD-L1+  tumor  section;  added  therapy  options  for  MET  and  RET  mutations  in  Targetable  Genetic  Mutation  sectionSmall  Cell  Lung  Cancer  Table  146-6  and  Extensive  Disease  section:  added  information  about  chemotherapy  +  durvalumab  and  lurbinectedin  to  table  and  text  and  updated  second-line  options  for  extensive  disease